JP2018171062A5 - - Google Patents

Download PDF

Info

Publication number
JP2018171062A5
JP2018171062A5 JP2018109490A JP2018109490A JP2018171062A5 JP 2018171062 A5 JP2018171062 A5 JP 2018171062A5 JP 2018109490 A JP2018109490 A JP 2018109490A JP 2018109490 A JP2018109490 A JP 2018109490A JP 2018171062 A5 JP2018171062 A5 JP 2018171062A5
Authority
JP
Japan
Prior art keywords
cell population
test
cancer cells
domain peptide
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018109490A
Other languages
English (en)
Japanese (ja)
Other versions
JP6684857B2 (ja
JP2018171062A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018171062A publication Critical patent/JP2018171062A/ja
Publication of JP2018171062A5 publication Critical patent/JP2018171062A5/ja
Application granted granted Critical
Publication of JP6684857B2 publication Critical patent/JP6684857B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018109490A 2012-09-19 2018-06-07 ダイナミックｂｈ３プロファイリング Active JP6684857B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702967P 2012-09-19 2012-09-19
US61/702,967 2012-09-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015533194A Division JP6352924B2 (ja) 2012-09-19 2013-09-19 ダイナミックｂｈ３プロファイリング

Publications (3)

Publication Number Publication Date
JP2018171062A JP2018171062A (ja) 2018-11-08
JP2018171062A5 true JP2018171062A5 (https=) 2018-12-20
JP6684857B2 JP6684857B2 (ja) 2020-04-22

Family

ID=49304346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015533194A Active JP6352924B2 (ja) 2012-09-19 2013-09-19 ダイナミックｂｈ３プロファイリング
JP2018109490A Active JP6684857B2 (ja) 2012-09-19 2018-06-07 ダイナミックｂｈ３プロファイリング

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015533194A Active JP6352924B2 (ja) 2012-09-19 2013-09-19 ダイナミックｂｈ３プロファイリング

Country Status (7)

Country Link
US (2) US10393733B2 (https=)
EP (1) EP2898327A1 (https=)
JP (2) JP6352924B2 (https=)
AU (1) AU2013317985B2 (https=)
CA (1) CA2885230C (https=)
HK (1) HK1213046A1 (https=)
WO (1) WO2014047342A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
HK1213046A1 (zh) 2012-09-19 2016-06-24 Dana-Farber Cancer Institute, Inc. 動態bh3分析
WO2015010094A1 (en) * 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
CA2922503C (en) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
US20180100859A1 (en) * 2015-03-24 2018-04-12 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
US9901574B2 (en) 2015-04-20 2018-02-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
AU2016253957C1 (en) 2015-04-27 2021-04-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3385715A1 (en) 2017-04-04 2018-10-10 Medizinische Hochschule Hannover Analytical process for predicting the therapeutic effect of bh3 mimetics
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP7589159B2 (ja) * 2019-02-26 2024-11-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP4306953A1 (en) 2022-07-12 2024-01-17 Fundació Institut de Bioenginyeria de Catalunya (IBEC) Real-time tracking of apoptosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
EP0799422A1 (en) 1995-10-24 1997-10-08 Sangstat Medical Corporation Anti alpha-galactosyl screening technique
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1999014321A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
WO2000059526A1 (en) 1999-04-07 2000-10-12 Thomas Jefferson University Enhancement of peptide cellular uptake
AU6906100A (en) 1999-08-16 2001-03-13 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
WO2002020568A2 (en) 2000-09-06 2002-03-14 Abbott Laboratories Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
WO2003040168A2 (en) 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
WO2003055515A1 (en) 2001-12-21 2003-07-10 Arius Research, Inc. Individualized anti-cancer antibodies
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1608969A4 (en) 2003-03-19 2007-06-06 Alfa Wassermann Inc SEPARATION AND ACCUMULATION OF SUB-CELLULAR COMPONENTS, AND PROTEINS WHICH ARE DRAWN THEREFROM
EP1997828B1 (en) 2003-11-05 2017-10-04 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides from BCL-2 and uses thereof
US7714005B2 (en) * 2004-12-22 2010-05-11 The Ohio State University Research Foundation Small molecule Bcl-xL/Bcl-2 binding inhibitors
JP2005130867A (ja) 2005-02-16 2005-05-26 Mitokor ミトコンドリア内カルシウムを使用するスクリーニングアッセイ
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
US20070027175A1 (en) 2005-07-27 2007-02-01 Shaughnessy John Jr Antineoplastic activities of ellipticine and its derivatives
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
KR100786759B1 (ko) 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
WO2008152405A2 (en) 2007-06-15 2008-12-18 The Queen's University Of Belfast Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases
US8466140B2 (en) 2007-09-10 2013-06-18 University Of Massachusetts Mitochondria-targeted anti-tumor agents
JP5783721B2 (ja) 2007-09-26 2015-09-24 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｂｃｌ−２ファミリーポリペプチドを調節する方法及び組成物
JP2009240173A (ja) 2008-03-28 2009-10-22 Univ Of Tokushima パーキン蛋白の新規糖化因子
SG176801A1 (en) 2009-06-11 2012-01-30 Minerva Biotechnologies Corp Methods for culturing stem and progenitor cells
WO2010147961A1 (en) 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
US20130122492A1 (en) 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
KR102062416B1 (ko) * 2012-05-10 2020-01-03 유트로픽스 파마슈티컬스, 인크. 실용 가능한 암 진단 대체 법
US20150322479A1 (en) 2012-06-20 2015-11-12 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
HK1213046A1 (zh) 2012-09-19 2016-06-24 Dana-Farber Cancer Institute, Inc. 動態bh3分析
JP6327662B2 (ja) 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
WO2015010094A1 (en) 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
CA2922503C (en) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
AU2016253957C1 (en) 2015-04-27 2021-04-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
US11092602B2 (en) 2015-07-06 2021-08-17 Whitehead Institute For Biomedical Research Methods and compositions relating to proteasome inhibitor resistance
JP7589159B2 (ja) 2019-02-26 2024-11-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング

Similar Documents

Publication Publication Date Title
JP2018171062A5 (https=)
Hu et al. The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we?
Behrend et al. Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells
Doyle et al. Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics
Hu et al. Epithelial‐mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1
Basturk et al. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis
Stella et al. MET mutations in cancers of unknown primary origin (CUPs)
Shang et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients
JP2015531606A5 (https=)
ES3023842T3 (en) Methods for prostate cancer detection and treatment
Brisam et al. Expression of MAGE-A1-A12 subgroups in the invasive tumor front and tumor center in oral squamous cell carcinoma
Freier et al. Immunohistochemical evaluation of the role of p53 mutation in cervical cancer: Ser-20 p53-mutant correlates with better prognosis
Liu et al. Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck
Horibe et al. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy
Rezaei et al. Identification of antibody reactive proteins in pancreatic cancer using 2D immunoblotting and mass spectrometry
Jin et al. Decreased Eph receptor-A1 expression is related to grade in ovarian serous carcinoma
Ye et al. Silencing SATB1 influences cell invasion, migration, proliferation, and drug resistance in nasopharyngeal carcinoma
Holck et al. IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy
Marioni et al. Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges
Wang et al. Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma
Wang et al. XB130 expression in human osteosarcoma: A clinical and experimental study
Yang et al. Higher expression of Caveolin-1 inhibits human small cell lung cancer (SCLC) apoptosis in vitro
Graveel et al. Identification and characterization of CRG-L2, a new marker for liver tumor development
Li et al. Under‐expression of annexin A2 is associated with Kazakh's esophageal squamous cell carcinoma
Pathak et al. Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific